Karyopharm Therapeutics Inc
KPTI
Get informed when a big investor buys or sells
+ FollowMarket Cap$215.52M
Close$
$1.36
80.8% downside
Current Fair Value
80.8% downsideOvervalued by 80.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $215.52 Million |
|---|---|
| Enterprise Value | $355.55 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.93 |
| Beta | 0.81 |
| Outstanding Shares | 22,014,000 |
Return
| Return on Equity | 73.39% |
|---|---|
| Return on Assets | -148.36% |
| Return on Invested Capital | -597.16% |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | 14.05 |
| Price to Sales | 1.18 |
| Price to Book Ratio | -0.55 |
| Enterprise Value to Revenue | 2.35 |
| Enterprise Value to EBIT | -4.22 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.65 |
| Debt to Equity | -0.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.45
Average shareholder expectationRevenue Estimate
$31.40 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-1.24
Average shareholder expectationRevenue Estimate
$34.78 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4007▼ 62.26% |
|---|---|
| Total Calls | 4,954,810▲ 1066.94% |
| Total Puts | 1,985,400▲ 356.94% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.27%▲ 30.61% |
|---|---|
| Total Invested | $102.11M▲ 46.69% |
| Investors Holding | 100▲ 24.00% |
ESG Score
No data
About Karyopharm Therapeutics Inc
CEO: Michael Kauffman